Welcome to our dedicated page for Indivior SEC filings (Ticker: INDV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Indivior’s filings rarely start with simple numbers—they dive straight into opioid-treatment revenues, clinical-trial minutiae, and litigation updates that can sway valuations overnight. Finding the paragraph that explains patent expiry or the table that breaks out Suboxone sales often means scrolling through hundreds of pages. Stock Titan condenses those complexities into clear takeaways, so you can grasp material events without forensic reading.
Need the latest Indivior quarterly earnings report 10-Q filing or its blockbuster annual report 10-K simplified? They’re here, updated from EDGAR in real time and paired with AI text that translates accounting language into plain English. Our engine pinpoints opioid settlement provisions, breaks down regional sales trends, and flags any Indivior 8-K material events explained within minutes of release. You’ll also find Indivior insider trading Form 4 transactions—each alert showing executive stock movements, with context from past patterns.
Curious about governance? The Indivior proxy statement executive compensation is parsed to show pay structures and performance metrics, while Indivior Form 4 insider transactions real-time dashboards highlight buying or selling before FDA milestones. Add in side-by-side comparisons, keyword search, and downloadable tables, and you have the tools to perform fast Indivior earnings report filing analysis. Whether you’re understanding Indivior SEC documents with AI for the first time or refining an existing model, Stock Titan delivers every filing type�10-K, 10-Q, 8-K, S-1, and more—complete, searchable, and explained simply.
The filing reports that The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC jointly beneficially own 9,789,169 ordinary shares of Indivior PLC, representing approximately 7.8% of the class. The statement shows shared voting power of 9,789,144 shares and shared dispositive power of 9,789,169 shares, with no sole voting or sole dispositive power reported.
Exhibits identify the GS Group as a parent holding company and Goldman Sachs & Co. LLC as a broker-dealer and registered investment adviser. The filing includes a joint filing agreement and a certification that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control. The statement provides ownership disclosure but does not disclose acquisition terms or strategic plans.
Q2 2025 snapshot: Net revenue rose 1% YoY to $302 m as SUBLOCADE sales grew 9% to $209 m, offsetting softer U.S. sublingual products. Gross margin expanded to 83% (74% last year) after prior-year PERSERIS exit costs rolled off. Operating income swung to $72 m from a $(118) m loss and diluted EPS reached $0.14 versus $(0.72). For the first half, revenue slipped 3% to $568 m but EPS improved to $0.52.
Cash & leverage: Operating cash flow jumped to $233 m, aided by delayed rebate payments, taking cash to $510 m and creating net cash of roughly $184 m against $326 m total debt. Capital-expenditure guidance remains $50-70 m for FY25, mainly for SUBLOCADE capacity.
Legal & tax items: Antitrust liabilities are down to an NPV of $20 m, and a $79 m provision covers opioid-MDL settlement offers. New dental-injury MDL (�21,000 plaintiffs) and U.K. shareholder suits introduce fresh uncertainty. A £33 m HMRC reserve pushed the effective tax rate to 71%.
Strategic moves: LSE delisting completed; the company joins the Russell 2000/3000 and will lose foreign-private-issuer status in 2026. Manufacturing footprint is being consolidated; a Curia supply contract ends January 2026 without material penalties.
Management outlook: Guidance implies gross margin in the low-to-mid-80% range, SG&A/R&D below 2024, and continued double-digit SUBLOCADE growth sufficient to offset mature-product erosion. Management does not expect material impact from new U.S. tax legislation.
Indivior announced two significant board-related developments in this 8-K filing. Stuart A. (Tony) Kingsley has been appointed as a non-executive director effective July 1, 2025. His appointment aligns with the Amended and Restated Relationship Agreement with Oaktree Value Opportunities Fund and related entities.
The company also disclosed new director equity arrangements:
- Five U.S.-based non-executive directors (Keith Humphreys, Daniel Ninivaggi, Barbara Ryan, Mark Stejbach, and David Wheadon) entered into a Purchase Plan with J.P. Morgan Securities for quarterly stock purchases
- The plan allows directors to defer approximately 70-80% of their after-tax base retainer into company shares
- U.K.-based director Juliet Thompson and related party Timothy Thompson purchased 1,925 and 3,850 Ordinary Shares respectively, with company reimbursement planned over the next year
These arrangements demonstrate a strategic move to increase share ownership among non-executive directors, aligning with the 2025 Directors' Remuneration Policy approved by shareholders.
FAQ
What is the current stock price of Indivior (INDV)?
What is the market cap of Indivior (INDV)?
